BioArctic AB (BIOA_B) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Bioarctic Ab Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.448 -- 00:00:06.113 Thank you so much. Good morning and welcome to Biotic's presentation for the first quarter 00:00:06.113 -- 00:00:08.135 of 2025. 00:00:08.135 -- 00:00:13.180 Biotic has now entered a new era, an era of profitable growth, which 00:00:13.180 -- 00:00:18.345 is signified by an extraordinarily strong first quarter and a lot of activities 00:00:18.345 -- 00:00:21.789 throughout the different parts of the business. 00:00:21.789 -- 00:00:26.677 I will talk more about that in today's presentation and we take the next slide, please. 00:00:26.677 -- 00:00:30.782 I'm Gunilla Oswald, I'm the CEO of Biotic, and I will share today's presentation with 00:00:30.782 -- 00:00:34.947 our CFO, Anders Martin Lööf. Next slide, please. 00:00:34.947 -- 00:00:38.772 Biotic is listed at Nasdaq Stockholm large cap, and this is our disclaimer. 00:00:38.772 -- 00:00:41.095 Next slide, please. 00:00:41.095 -- 00:00:46.381 As I just said, Biotic has now entered a new era, an era of profitable growth 00:00:46.381 -- 00:00:51.568 with continuous and increasing royalties, also supported by milestones, 00:00:51.568 -- 00:00:57.203 which is reflecting the benefit of our successful partnership business model. 00:00:57.203 -- 00:01:02.228 This enables even further activities across the business as we develop new and better 00:01:02.228 -- 00:01:07.413 treatments for patients in an increasing number of severe brain disorders. 00:01:07.413 -- 00:01:10.616 Let's look at some of the highlights this year. 00:01:10.616 -- 00:01:12.878 First of all, Lekembe 00:01:12.878 -- 00:01:18.323 is now approved in all major markets, including US, Japan, China, 00:01:18.323 -- 00:01:23.348 and Europe. We see continued growth across markets and more and more patients 00:01:23.348 -- 00:0...